Guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with Tnf-Á blockers

Harefuah

Volumn 146, Issue 3, 2007, Pages 235-237

  Elkayam, Ori ^a   Balbir Gurman, Alexandra ^b   Lidgi, Moshe ^c   Rahav, Galia ^d   Weiler Ravel, Daniel ^e  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c Tel Aviv University Sackler Faculty of Medicine

^d SHEBA MEDICAL CENTER   (Israel)

^e CARMEL MEDICAL CENTER   (Israel)

Author keywords

Anti TNF ; Prevention guidelines; Tuberculosis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ANTAGONISM; HUMAN; ISRAEL; MEDICAL SOCIETY; PRACTICE GUIDELINE; RHEUMATOLOGY; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOGLOBULIN G; ISRAEL; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOLOGY; SOCIETIES, MEDICAL; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547456898     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Keane J, Gershon S, Pharm D & al, Tuberculosis associated with Infliximab, a tumor necrosis factor α neutralizing agent. NEJM, 345; 15: 1098-1104.
2. Centers for Disease Control and Prevention (CDC), Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep, 2004 53: 683-6.
3. Bieber J & Kavanaugh A, Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin N Am, 2004; 30: 257-270.
4. Wolfe F, Michaud K, Anderson J & Urbansky K, Tuberculosis infection in patients with rheumatoid arthritis and the effect of Infliximab therapy. Arthritis Rheum, 2004; 50: 372-9.
5. Gardam M, Keystone EC, Menzies R & al, Anti-tumor necrosis factor agents and tuberculosis risks: mechanism of action and clinical management. Lancet, 2003; 3: 148-55.
6. Hamilton CD, Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum, 2003; 48: 2085-2091.
7. Center for disease control and prevention, Diagnosis of tuberculosis infection and disease. 2001, Oct 24.
8. Ledingham J, Wilkinson C & Deighton C, British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNFα treatments. Rheumatology, 2005; 44: 1205-1206.
9. Winkelstein A, Effects of cytotoxic immunosuppressants on tuberculin-sensitive lymphocytes in guinea pigs. J Clin Invest, 1975; 56: 1587-96.
10. Salmon D, Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine, 2002; 69: 170-2.
11. Bibi H, Weiler-Ravell D, Shoseyov D & al, Compliance to treatment of latent tuberculosis infection in a region of Israel. Isr Med Assoc J, 2002; 4: 13-6.
12. Mohan AK, Cote TR, Block JA & al, Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis, 2004; 39: 295-9. Epub 2004 Jul 16.